» Articles » PMID: 37635904

Peripheral Metabolic Alterations Associated with Pathological Manifestations of Parkinson's Disease in Gut-brain Axis-based Mouse Model

Overview
Specialty Molecular Biology
Date 2023 Aug 28
PMID 37635904
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Parkinson's disease (PD) is a representative neurodegenerative disease, and its diagnosis relies on the evaluation of clinical manifestations or brain neuroimaging in the absence of a crucial noninvasive biomarker. Here, we used non-targeted metabolomics profiling to identify metabolic alterations in the colon and plasma samples of ()-treated mice, which is a possible animal model for investigating the microbiota-gut-brain axis.

Methods: We performed gas chromatography-mass spectrometry to analyze the samples and detected metabolites that could reflect -induced disease progression and pathology.

Results And Discussion: Pattern, correlation and pathway enrichment analyses showed significant alterations in sugar metabolism such as galactose metabolism and fructose and mannose metabolism, which are closely associated with energy metabolism and lipid metabolism. This study indicates possible metabolic factors for -induced pathological progression and provides evidence of metabolic alterations associated with -mediated pathology of brain neurodegeneration.

Citing Articles

Multi-Omics Analysis of the Gut-Brain Axis Elucidates Therapeutic Mechanisms of Guhong Injection in the Treatment of Ischemic Stroke.

Mao P, Hu J, Mai X, Li N, Liao Y, Feng L Int J Mol Sci. 2025; 26(4).

PMID: 40004026 PMC: 11855775. DOI: 10.3390/ijms26041560.


Intravenous MSC-Treatment Improves Impaired Brain Functions in the R6/2 Mouse Model of Huntington's Disease via Recovered Hepatic Pathological Changes.

Yu-Taeger L, El-Ayoubi A, Qi P, Danielyan L, Nguyen H Cells. 2024; 13(6.

PMID: 38534313 PMC: 10969189. DOI: 10.3390/cells13060469.

References
1.
Trezzi J, Galozzi S, Jaeger C, Barkovits K, Brockmann K, Maetzler W . Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease. Mov Disord. 2017; 32(10):1401-1408. DOI: 10.1002/mds.27132. View

2.
Ju I, Lee M, Jeon S, Huh E, Kim J, Lee J . GC-TOF-MS-Based Metabolomic Analysis and Evaluation of the Effects of HX106, a Nutraceutical, on ADHD-Like Symptoms in Prenatal Alcohol Exposed Mice. Nutrients. 2020; 12(10). PMC: 7600704. DOI: 10.3390/nu12103027. View

3.
Shao Y, Li T, Liu Z, Wang X, Xu X, Li S . Comprehensive metabolic profiling of Parkinson's disease by liquid chromatography-mass spectrometry. Mol Neurodegener. 2021; 16(1):4. PMC: 7825156. DOI: 10.1186/s13024-021-00425-8. View

4.
Espay A, Kalia L, Gan-Or Z, Williams-Gray C, Bedard P, Rowe S . Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?. Neurology. 2020; 94(11):481-494. PMC: 7220234. DOI: 10.1212/WNL.0000000000009107. View

5.
Chang K, Cheng M, Tang H, Huang C, Wu Y, Chen C . Alternations of Metabolic Profile and Kynurenine Metabolism in the Plasma of Parkinson's Disease. Mol Neurobiol. 2018; 55(8):6319-6328. DOI: 10.1007/s12035-017-0845-3. View